The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 435 participants.

Also called NCT01618162

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 435 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01618162
  • EudraCT 2012-000140-97
Other papers using this trial's data
  • Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial Diabetic medicine : a journal of the British Diabetic Association, 2017-02 DOI, PubMed 27589252, PMC5811787 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Bulgaria, Canada, Germany, India, Israel, Puerto Rico, Türkiye (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01618162. Randomized; double masking; primary purpose treatment. Start 2012-08-29 (actual); primary completion 2013-10-23 (actual). Results posted on 2017-02-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy
Acronym
DUAL™IV
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
insulin degludec/liraglutide
Intervention (Drug)
placebo
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct01618162
Content hash
604c795de2e3d9be73152ab6b8e8260d57fdb8b4af26af116276729856fed7ac